Company news
Polyrizon Ltd. (NASDAQ:PLRZ) news
Polyrizon Ltd. news releases on 6ix. Latest, Apr 25, 2025: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal…
Press releases — page 2
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
April 25, 2025
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
April 11, 2025
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
April 2, 2025
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
April 1, 2025
Polyrizon Ltd. Announces $17.0 Million Private Placement
March 31, 2025
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
March 27, 2025
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
March 25, 2025
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
March 18, 2025
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
March 14, 2025
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
March 13, 2025
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
March 11, 2025
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
March 10, 2025
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
January 29, 2025
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
January 22, 2025
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
December 29, 2024
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
December 18, 2024
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
December 17, 2024
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
December 12, 2024
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
December 1, 2024
Polyrizon Announces Closing of $4.2 Million Initial Public Offering
October 29, 2024